Abstract:Abstract Aim We aimed to compare the effects and underlying mechanisms of 6 different representative HDAC inhibitors (MS-275, MC-1568, Tubastatin-A (Tub-A), EX-527, Vorinostat Suberoylanilide hydroxamic acid (SAHA) and Valproic Acid (VPA)) in hypoxia-induced intestinal epithelial barrier dysfunction based on in vitro Caco-2 cell experiments and network pharmacology combined with bioinformatics analysis. Methods In vitro study: Human intestinal epithelial cells (Caco-2) were divided into 3 groups: (1) sham (normoxia); (2) vehicle (anoxia, with DMSO treatment), and (3) treatment (anoxia, and treatment with 5 μmol/L MS-275, MC-1568, Tub-A, EX-527, SAHA and VPA). After 12 h in an anoxic chamber, the cells were examined for epithelial permeability, cellular viability, cytotoxicity and tight junction component Claudin-3 protein expression. Network pharmacology study: The structures of HDAC inhibitors were downloaded from NCBI-PubChem compound databases (https://www.ncbi.nlm.nih.gov/pccompound/). The possible targets of the core active ingredients of HDAC inhibitors were obtained from PharmMapper (http://www.lilab-ecust.cn/pharmmapper/index.html) and SuperPred (https://prediction.charite.de). The compound-target network was constructed by Cytoscape software version 3.8.2. Full gene names corresponding to these human-derived target proteins were obtained from the UniProt database (https://www.uniprot.org/). An UpSet diagram of all the human-derived target proteins obtained from PharmMapper and SuperPred was constructed using R software version 3.6.3 (R package: UpSetR (v1.4.0)). Functional annotation information was obtained from Gene Ontology (GO) (http://geneontology.org/) and KEGG (https://www.kegg.jp/) databases. To predict the underlying biological function and corresponding pathways of these significant genes, the DAVID database and Merascape were introduced to perform functional enrichment analysis, including three GO terms (BP: biological process; CC: cellular component; MF: molecular function) and KEGG pathways. Results In vitro study: In cultured Caco-2 cells, anoxia markedly increased the permeability of Caco-2 monolayer cells (P=0.000), while Tub-A, SAHA and VPA significantly attenuated the alteration (P=0.021, 0.000, 0.017). Anoxia significantly decreased cellular viability (P=0.000) and increased cytotoxicity (P=0.000) compared to the sham group, while MC-1568, Tub-A, EX-527 and VPA treatment offered significant protection. Moreover, the expression of Claudin-3 was markedly decreased in vitro compared to that in the sham group, whereas this decrease was significantly attenuated by Tub-A (P =0.002). Network pharmacology study: The “Herbs-Components-Targets” network of HDAC inhibitors from the PharmMapper database included 116 nodes and 287 edges. In the SuperPred database, the “Herbs-Components-Targets” network included 124 nodes and 158 edges. Six genes were selected by taking the intersection of 6 HDAC inhibitor key target gene sets from PharmMapper. Twelve genes were selected from SuperPred by taking the intersection of 4 HDAC inhibitor key target gene sets. GO and KEGG enrichment analyses were conducted to identify 6 target genes from PharmMapper and 12 target genes from SuperPred. Conclusion HDAC inhibitors can promote cellular viability and prevent the loss of intestinal TJ proteins during anoxia. Based on the existing recognized public databases and bioinformatics analysis of the structure, target proteins and functions of different HDAC inhibitors, specific genes and functional pathways could be involved in the underlying mechanism.

Inositol Hexaphosphate (InsP6) Activates the HDAC1/3 Epigenetic Axis to Maintain Intestinal Barrier Function

Inositol Hexakisphosphate Kinase 1 (ip6k1) Regulates Inositol Synthesis in Mammalian Cells

IPMK regulates HDAC3 activity and histone H4 acetylation in human cells

A Clade of Receptor-Like Cytoplasmic Kinases and 14-3-3 Proteins Coordinate Inositol Hexaphosphate Accumulation

Inositol Hexaphosphate Promotes Intestinal Adaptation in Short Bowel Syndrome Via an HDAC3-mediated Epigenetic Pathway

Gut Epithelial Inositol Polyphosphate Multikinase Alleviates Experimental Colitis via Governing Tuft Cell Homeostasis

Inositol hexakisphosphate (IP6) generated by IP5K mediates cullin-COP9 signalosome interactions and CRL function

JAK-STAT Pathway Inhibition Partially Restores Intestinal Homeostasis in Hdac1- and Hdac2-Intestinal Epithelial Cell-Deficient Mice

The Cytoplasmic Deacetylase HDAC6 is Required for Efficient Oncogenic Tumorigenesis

PIM1-HDAC2 axis modulates intestinal homeostasis through epigenetic modification

Targeting the Inositol Pyrophosphate Biosynthetic Enzymes in Metabolic Diseases

Abstract 4582: HDAC6 inhibition reshapes the epigenome of cancer via P300 stabilization

Loss-of-function of inositol polyphosphate-4-phosphatase reversibly increases the severity of allergic airway inflammation

P031 CKD-506, a new histone deacetylase 6 inhibitor, suppresses immune cells and restores intestinal epithelial function

HDAC6 deacetylates IDH1 to promote the homeostasis of hematopoietic stem and progenitor cells

Histone Deacetylases in the Inflamed Intestinal Epithelium-Promises of New Therapeutic Strategies

The Ip6k1 and Ip6k2 Kinases Are Critical for Normal Renal Tubular Function

KO of 5-Insp7 Kinase Activity Transforms the HCT116 Colon Cancer Cell Line into a Hypermetabolic, Growth-Inhibited Phenotype

Inositol Hexaphosphate Inhibits Proliferation and Induces Apoptosis of Colon Cancer Cells by Suppressing the AKT/mTOR Signaling Pathway

The Effects of Different Histone Deacetylase Inhibitors on Hypoxia-induced Intestinal Epithelial Barrier Dysfunction and a Preliminary Exploration of the Mechanisms

HDAC6 inhibition disrupts HDAC6-P300 interaction reshaping the cancer chromatin landscape